Farage (ATCC® CRL-2630)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Tissue: derived from metastatic site: lymph node  /  Disease: non-Hodgkin's B cell lymphoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue derived from metastatic site: lymph node
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Epstein-Barr virus (EBV)]
Disease non-Hodgkin's B cell lymphoma
Age adult
Gender female
Ethnicity White
Karyotype trisomy of chromosome 11 RefGabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273
Derivation
The Farage cell line was adapted to culture in 1990 from a lymph node biopsy of a patient with diffuse large cell non-Hodgkin's lymphoma (DLCL).
Clinical Data
adult
female
White
Antigen Expression
CD10 +/-; CD11a + (LFA-1); CD19 +; CD20 +; CD21 +; CD22 +; CD23 +; CD29 (VLA-4) +; CD38 +; CD39 +; CD40 +; CD44 +; CD54 + (ICAM-1); CD58 + (LFA-3); CD23 -; HLA DR +
Comments
The cells do not express surface or cytoplasmic immunoglobulin.

Exposure to IL-4 augmented the concentrations of CD23, CD54, and CD58 but diminished the expression of CD21, CD22, and CD38. Incubation with IL-4 for 6 to 8 days led to increased expression of CD11a, CD39, CD40, and to disappearance of CD21 and CD38.

Exposure of Farage cells to phorbol 12-myristate 13-acetate (PMA) down-regulated CD21 and CD23 expression.

They do not express the terminal deoxynucleotydyl transferase gene (TdT), nor the recombination activating genes RAG-1 and RAG-2, known as markers of the pre-B cell stage. These results show that Farage represents a mature B-cell rather than a pre-B cell.

The cells are positive for Epstein-Barr virus (EBV).
mature B cell
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 - 5 x 105 viable cells/mL. Maintain cell density between 3 x 105 and 3 x 106 viable cells/mL.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 11,13
D16S539: 11,12
D5S818: 12
D7S820: 12
THO1: 8,9
TPOX: 9
vWA: 14,15
Population Doubling Time 24 to 36 hrs
Name of Depositor H Ben-Bassat
Year of Origin 1990
References

Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ("Farage") lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715

Shubinsky G, et al. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823

Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283

Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ("Farage") lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715

Shubinsky G, et al. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823

Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283

Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273